Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure

What Was Tested

The paper reports a study of ANP (Atrial Natriuretic Peptide) in the context of low blood pressure and orthostatic hypotension, published as a randomized controlled trial.

Who Took Part

The study group was 6 patients.

PubMed indexes the participants as middle-aged adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

The patients were allocated by chance, so the ANP (Atrial Natriuretic Peptide) group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received ANP (Atrial Natriuretic Peptide).

A placebo (an inactive look-alike) gave the ANP (Atrial Natriuretic Peptide) group a baseline to be compared against.

In the crossover set-up each of the patients took both ANP (Atrial Natriuretic Peptide) and the comparison in turn, acting as their own control.

What Was Measured

The subject headings attached to it are Atrial Natriuretic Factor, Blood Pressure, Cyclic GMP, Dioxolanes, Dipeptides, Epinephrine and Glomerular Filtration Rate.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of ANP (Atrial Natriuretic Peptide) in 6 patients in people with low blood pressure and orthostatic hypotension.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1992 (Journal of cardiovascular pharmacology), a journal based in United States.

More context: the ANP (Atrial Natriuretic Peptide) compound page, Low blood pressure and orthostatic hypotension research.